The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Gemcitabine, paclitaxel, and doxorubicin as first-line therapy for patients with advanced urothelial carcinoma and renal insufficiency: A phase II study.
Lance C. Pagliaro
No relevant relationships to disclose
Mark F. Munsell
No relevant relationships to disclose
Deborah Harris
No relevant relationships to disclose
Robert L. Carolla
No relevant relationships to disclose
Arlene O. Siefker-Radtke
No relevant relationships to disclose